TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Innovative Pulmonary Rehabilitation Telehealth Program for Improving COPD Patient Outcomes
Brief Summary: Researchers want to learn more about telehealth pulmonary rehabilitation programs that help people with Chronic obstructive pulmonary disease (COPD) improve physical activity and quality of life.


Options:
A: Arm Label: COPD Telehealth Program; Type: EXPERIMENTAL; Interventions: Behavioral: Telehealth Program | Intervention Type: BEHAVIORAL; Name: Telehealth Program; Assigned to Arm(s): COPD Telehealth Program
B: Arm Label: COPD Web; Type: EXPERIMENTAL; Interventions: Behavioral: COPD Web | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: COPD Web; Assigned to Arm(s): COPD Web
C: Arm Label: comprehensive care programme; Type: ACTIVE_COMPARATOR; Interventions: Other: Comprehensive care programme | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive care programme; Assigned to Arm(s): comprehensive care programme
D: Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Internet-mediated Walking Program; Type: OTHER; Interventions: Behavioral: automated internet-mediated walking program | Intervention Type: BEHAVIORAL; Name: automated internet-mediated walking program; Assigned to Arm(s): Internet-mediated Walking Program | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery: a Multi Center Double-Blinded Randomized Controlled Trial (PREPACOL2 Study)
Brief Summary: This study aims to demonstrate that a preoperative combination of mechanical bowel preparation and oral antibiotics, before elective laparoscopic rectal cancer surgery, is associated with a reduction of postoperative surgical site infection rate, as compared to mechanical bowel preparation alone Our hypothesis is that a preoperative colonic preparation including a combination of mechanical bowel preparation and oral antibiotics before elective laparoscopic rectal cancer surgery is associated with a reduced rate of 30-day postoperative surgical site infection, as compared to mechanical bowel preparation alone


Options:
A: Intervention Type: DRUG; Name: polyethylene glycol bowel lavage solution; Assigned to Arm(s): N/A
B: Arm Label: Oral Antibiotics; Type: N/A; Interventions: Drug: Paromomycin Sulfate Powder | Arm Label: iv Antibiotics; Type: N/A; Interventions: N/A | Intervention Type: DRUG; Name: Paromomycin Sulfate Powder; Assigned to Arm(s): Oral Antibiotics
C: Arm Label: oral antibiotics+mechanical bowel preparation; Type: EXPERIMENTAL; Interventions: Drug: Neomycin,metronidazole | Arm Label: simple mechanical bowel preparation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Neomycin,metronidazole; Assigned to Arm(s): oral antibiotics+mechanical bowel preparation
D: Arm Label: 1) " MBP and oral antibiotics " group; Type: EXPERIMENTAL; Interventions: Drug: Sennosides colonic preparation, Drug: Oral Gentamycin, Drug: Oral Ornidazole | Arm Label: 2) " MBP alone " group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sennosides colonic preparation, Drug: Oral Placebo Gentamycin, Drug: Oral Placebo Ornidazole | Intervention Type: DRUG; Name: Sennosides colonic preparation; Assigned to Arm(s): 1) " MBP and oral antibiotics " group, 2) " MBP alone " group | Intervention Type: DRUG; Name: Oral Gentamycin; Assigned to Arm(s): 1) " MBP and oral antibiotics " group | Intervention Type: DRUG; Name: Oral Ornidazole; Assigned to Arm(s): 1) " MBP and oral antibiotics " group | Intervention Type: DRUG; Name: Oral Placebo Gentamycin; Assigned to Arm(s): 2) " MBP alone " group | Intervention Type: DRUG; Name: Oral Placebo Ornidazole; Assigned to Arm(s): 2) " MBP alone " group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder
Brief Summary: This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB.


Options:
A: Arm Label: Gabapentin; Type: EXPERIMENTAL; Interventions: Drug: Gabapentin | Arm Label: Solifenacin Succinate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin Succinate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo drugs | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Gabapentin | Intervention Type: DRUG; Name: Solifenacin Succinate; Assigned to Arm(s): Solifenacin Succinate | Intervention Type: DRUG; Name: Placebo drugs; Assigned to Arm(s): Placebo
B: Arm Label: solifenacin succinate (VESIcare); Type: EXPERIMENTAL; Interventions: Drug: solifenacin succinate (VESIcare) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: solifenacin succinate (VESIcare); Assigned to Arm(s): solifenacin succinate (VESIcare) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Vibegron + Placebo to match Tolterodine; Type: EXPERIMENTAL; Interventions: Drug: vibegron, Drug: Tolterodine placebo | Arm Label: Placebo to match vibegron + Placebo to match Tolterodine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vibegron placebo, Drug: Tolterodine placebo | Arm Label: Tolterodine + Placebo to match vibegron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vibegron placebo, Drug: Tolterodine Tartrate ER | Intervention Type: DRUG; Name: vibegron; Assigned to Arm(s): Vibegron + Placebo to match Tolterodine | Intervention Type: DRUG; Name: Vibegron placebo; Assigned to Arm(s): Placebo to match vibegron + Placebo to match Tolterodine, Tolterodine + Placebo to match vibegron | Intervention Type: DRUG; Name: Tolterodine Tartrate ER; Assigned to Arm(s): Tolterodine + Placebo to match vibegron | Intervention Type: DRUG; Name: Tolterodine placebo; Assigned to Arm(s): Placebo to match vibegron + Placebo to match Tolterodine, Vibegron + Placebo to match Tolterodine
D: Intervention Type: DRUG; Name: Tolterodine ER; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating an eHealth Breastfeeding Resource for Mothers, Fathers, Partners and Co-parents
Brief Summary: This trial will evaluate an eHealth breastfeeding co-parenting resource designed for mothers and their co-parents. Couples will be randomized to study groups and the intervention group will receive information about this resource or the control group will receive usual care. The primary outcomes will be exclusive breastfeeding at 4 and 24 weeks postpartum.


Options:
A: Arm Label: eHealth Intervention; Type: EXPERIMENTAL; Interventions: Other: eHealth Breastfeeding Co-parenting Resource | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: eHealth Breastfeeding Co-parenting Resource; Assigned to Arm(s): eHealth Intervention
B: Arm Label: Essential Health Care (EHC) only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mass media | Arm Label: EHC + Micronutrient Powders; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient powders, Behavioral: Mass media | Arm Label: EHC + BCC; Type: EXPERIMENTAL; Interventions: Behavioral: EHC + BCC, Behavioral: Mass media | Arm Label: EHC + BCC + Micronutrient powders; Type: EXPERIMENTAL; Interventions: Behavioral: EHC + BCC, Dietary Supplement: Micronutrient powders, Behavioral: Mass media | Intervention Type: BEHAVIORAL; Name: EHC + BCC; Assigned to Arm(s): EHC + BCC, EHC + BCC + Micronutrient powders | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient powders; Assigned to Arm(s): EHC + BCC + Micronutrient powders, EHC + Micronutrient Powders | Intervention Type: BEHAVIORAL; Name: Mass media; Assigned to Arm(s): EHC + BCC, EHC + BCC + Micronutrient powders, EHC + Micronutrient Powders, Essential Health Care (EHC) only
C: Arm Label: Breastfeeding promotion intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Breastfeeding promotion intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding promotion intervention; Assigned to Arm(s): Breastfeeding promotion intervention
D: Arm Label: implementation strategy; Type: EXPERIMENTAL; Interventions: Other: implementation strategy of Breastfeeding | Arm Label: Conventional intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: implementation strategy of Breastfeeding; Assigned to Arm(s): implementation strategy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Activity Across the Curriculum (PAAC 3):Teacher vs. Remotely Delivered Classroom Physical Activity Breaks
Brief Summary: The study is designed to compare two methods of delivering short (\~10 min) physical activity breaks that will occur during the regular school day for 3 years. Schools will be randomized to deliver physical activity breaks led by either the regular classroom teacher or by a remote instructor through a video in the classroom. Both delivery methods will promote a variety of whole body movements using large muscle groups. The schools will not be able to choose which group (regular teacher or remote instructor) they will be part of.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: CHAM JAM | Arm Label: Wait-Listed Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: CHAM JAM; Assigned to Arm(s): Intervention
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Active play in after school programs (ASP) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Active play in after school programs (ASP); Assigned to Arm(s): Intervention group
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Behavioral: Walking School Bus | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Walking School Bus; Assigned to Arm(s): I
D: Arm Label: PAAC-R; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Across the Curriculum | Arm Label: PAAC-T; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Across the Curriculum | Intervention Type: BEHAVIORAL; Name: Physical Activity Across the Curriculum; Assigned to Arm(s): PAAC-R, PAAC-T

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Placebo-controlled Treatment of Impulsivity in Adults With Probiotics
Brief Summary: A multicentre randomized double-blind placebo controlled parallel design (10 weeks) study investigating probiotic supplementation in highly impulsive adults (18-65 yrs; N=180). The probiotic studied is Synbiotic2000Forte that contain three well-studied anti-inflammatory lactic acid bacteria (LABs) and four fermentable fibers: Pediococcus pentosaceus 5-33:3, Lactobacillus paracasei subsp paracasei 19, and Lactobacillus plantarum 2362 in combination with the following four fermentable fibres: betaglucan, inulin, pectin and resistant starch. With this study we aim to detect, whether treatment with probiotics is effective in adults with high levels of impulsivity, compulsivity, and aggression.


Options:
A: Arm Label: Treatment with a probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Treatment with a probiotic | Arm Label: Treatment with placebo powder; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment with placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Treatment with a probiotic; Assigned to Arm(s): Treatment with a probiotic | Intervention Type: OTHER; Name: Treatment with placebo; Assigned to Arm(s): Treatment with placebo powder
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Assertive intervention | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard treatment | Intervention Type: BEHAVIORAL; Name: Assertive intervention; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): B
C: Arm Label: Immediate Functional Imagery Training (FIT); Type: EXPERIMENTAL; Interventions: Behavioral: Functional Imagery Training (FIT) | Arm Label: Delayed Functional Imagery Training (FIT); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Functional Imagery Training (FIT); Assigned to Arm(s): Immediate Functional Imagery Training (FIT)
D: Arm Label: No text messages; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Supportive and interactive text messages; Type: EXPERIMENTAL; Interventions: Other: Supportive and interactive text messages | Intervention Type: OTHER; Name: Supportive and interactive text messages; Assigned to Arm(s): Supportive and interactive text messages

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Placebo-controlled Treatment of Impulsivity in Adults With Probiotics
Brief Summary: A multicentre randomized double-blind placebo controlled parallel design (10 weeks) study investigating probiotic supplementation in highly impulsive adults (18-65 yrs; N=180). The probiotic studied is Synbiotic2000Forte that contain three well-studied anti-inflammatory lactic acid bacteria (LABs) and four fermentable fibers: Pediococcus pentosaceus 5-33:3, Lactobacillus paracasei subsp paracasei 19, and Lactobacillus plantarum 2362 in combination with the following four fermentable fibres: betaglucan, inulin, pectin and resistant starch. With this study we aim to detect, whether treatment with probiotics is effective in adults with high levels of impulsivity, compulsivity, and aggression.


Options:
A: Arm Label: Treatment with a probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Treatment with a probiotic | Arm Label: Treatment with placebo powder; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment with placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Treatment with a probiotic; Assigned to Arm(s): Treatment with a probiotic | Intervention Type: OTHER; Name: Treatment with placebo; Assigned to Arm(s): Treatment with placebo powder
B: Arm Label: ASAP Treatment and Brite; Type: EXPERIMENTAL; Interventions: Behavioral: As Safe As Possible, Behavioral: Brite | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: As Safe As Possible; Assigned to Arm(s): ASAP Treatment and Brite | Intervention Type: BEHAVIORAL; Name: Brite; Assigned to Arm(s): ASAP Treatment and Brite | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: General Psychiatric Management | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy | Intervention Type: BEHAVIORAL; Name: General Psychiatric Management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Omacor® | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Omacor® | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omacor®; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Recombinant Factor VIIa (rFVIIa) for Acute Hemorrhagic Stroke Administered At Earliest Time (FASTEST) Trial
Brief Summary: The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.


Options:
A: Arm Label: Prothrombin complex concentrate (PCC); Type: EXPERIMENTAL; Interventions: Drug: Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP) | Arm Label: Fresh frozen plasma (FFP); Type: EXPERIMENTAL; Interventions: Drug: Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP) | Intervention Type: DRUG; Name: Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP); Assigned to Arm(s): Fresh frozen plasma (FFP), Prothrombin complex concentrate (PCC)
B: Arm Label: Recombinant Activated Factor VII (rFVIIa); Type: ACTIVE_COMPARATOR; Interventions: Biological: Recombinant Activated Factor VII (rFVIIa) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Recombinant Activated Factor VII (rFVIIa); Assigned to Arm(s): Recombinant Activated Factor VII (rFVIIa) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Tranexamic Acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic Acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Saline 0.9%; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Tunneled Dialysis Catheters Versus Non-tunneled Dialysis Catheters for Renal Replacement Therapy in the ICU
Brief Summary: The investigators propose a randomized controlled trial to examine whether tunneled dialysis catheters should be first-line for acute kidney injury requiring renal replacement therapy (AKI-RRT) in the critical care setting, barring any clinical contraindications, compared to non-tunneled access. This randomized controlled trial will include patients admitted to an intensive care unit (ICU) at Brigham and Women's Hospital (BWH). The investigators will randomize all eligible consented incident patients with AKI requiring renal replacement therapy either to tunneled dialysis catheter or non-tunneled dialysis catheter placement. The inclusion criteria encompasses all adult patients in the BWH ICUs with an incident AKI requiring renal replacement therapy. The investigators' hypothesis is that the rate of overall complications is lower with tunneled dialysis catheters compared to non-tunneled catheters.


Options:
A: Arm Label: Tunneled dialysis catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Tunneled versus non-tunneled dialysis catheter insertion | Arm Label: Non-tunneled dialysis catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Tunneled versus non-tunneled dialysis catheter insertion | Intervention Type: DEVICE; Name: Tunneled versus non-tunneled dialysis catheter insertion; Assigned to Arm(s): Non-tunneled dialysis catheter, Tunneled dialysis catheter
B: Arm Label: CVVH arm; Type: ACTIVE_COMPARATOR; Interventions: Other: RRT for acute kidney failure using the CVVH method | Arm Label: IHD arm; Type: ACTIVE_COMPARATOR; Interventions: Other: RRT for acute kidney failure using the IHD (intermittent HD) | Intervention Type: OTHER; Name: RRT for acute kidney failure using the CVVH method; Assigned to Arm(s): CVVH arm | Intervention Type: OTHER; Name: RRT for acute kidney failure using the IHD (intermittent HD); Assigned to Arm(s): IHD arm
C: Arm Label: heparinized saline priming group; Type: EXPERIMENTAL; Interventions: Drug: heparinized saline priming group | Arm Label: nafamostat infusion group after heparinized saline priming; Type: ACTIVE_COMPARATOR; Interventions: Drug: nafamostat infusion after heparinized saline priming | Intervention Type: DRUG; Name: heparinized saline priming group; Assigned to Arm(s): heparinized saline priming group | Intervention Type: DRUG; Name: nafamostat infusion after heparinized saline priming; Assigned to Arm(s): nafamostat infusion group after heparinized saline priming
D: Arm Label: M100; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anticoagulation with nafamostat mesilate | Arm Label: HF1000; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation with nafamostat mesilate | Intervention Type: DRUG; Name: Anticoagulation with nafamostat mesilate; Assigned to Arm(s): HF1000, M100

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Achieving TB Control In Zambia Through Scale Up Of Innovative Tools And Proven Active TB Case Finding Interventions
Brief Summary: To achieve TB control, innovative case finding interventions are needed that will reach the broader affected population including those that do not access the health facilities. Systematic community case finding with highly sensitive screening and diagnostic tools are needed. At the facility level, the index of suspicion for TB by health care workers needs to be raised to ensure that all those that need TB screening are appropriately screened.


Options:
A: Arm Label: Standard Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Arm Label: Same-Day Treatment Group; Type: EXPERIMENTAL; Interventions: Other: Same-Day Treatment | Intervention Type: OTHER; Name: Same-Day Treatment; Assigned to Arm(s): Same-Day Treatment Group | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard Group
B: Arm Label: Community level screening; Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Screening at community level | Arm Label: Community level screening: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Screening at community level | Intervention Type: DIAGNOSTIC_TEST; Name: Screening at community level; Assigned to Arm(s): Community level screening: Arm 2, Community level screening; Arm 1
C: Arm Label: PLHIV Centralised Xpert Ultra; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PLHIV Point of Care Xpert Ultra; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: PLHIV Point of Care Xpert Ultra | Arm Label: PLHIV Centralised Xpert VL; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PLHIV Point of Care Xpert VL; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: PLHIV Point of Care Xpert VL | Intervention Type: DIAGNOSTIC_TEST; Name: PLHIV Point of Care Xpert Ultra; Assigned to Arm(s): PLHIV Point of Care Xpert Ultra | Intervention Type: DIAGNOSTIC_TEST; Name: PLHIV Point of Care Xpert VL; Assigned to Arm(s): PLHIV Point of Care Xpert VL
D: Arm Label: Intervention; Type: OTHER; Interventions: Diagnostic Test: LF-LAM | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIAGNOSTIC_TEST; Name: LF-LAM; Assigned to Arm(s): Intervention

Answer: B